News

Podcast

Diabetes Dialogue: Simplera CGM and Medtronic's Partnership with Abbott

In this episode, hosts take a break from the ADCES meeting to discuss the latest news from Medtronic related to their Simplera CGM and their partnership with Abbott.

On August 07, 2024, Medtronic announced the US Food and Drug Administration's approval of the Simplera continuous glucose monitor (CGM).

According to Medtronic, the CGM system, which is used as part of a Smart MDI system with the InPen smart insulin pen and the Simplera Sync sensor, is the company's first disposable, all-in-one CGM and is half the size of previous Medtronic CGMs. Medtronic also pointed out the Simplera CGM is designed to be used with the MiniMed 780G and will be available via a limited market release in the US beginning with existing standalone CGM and InPen customers once the updated InPen smart insulin pen app receives FDA clearance.

In the same press release, Medtronic also announced a new partnership with Abbott aimed at simplifying and expanding CGM options for people living with diabetes. With the new partnership, Abbott will supply Medtronic with a CGM that will work exclusively with Medtronic smart dosing devices and software across both automated insulin delivery and Smart MDI systems.

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, take a break from the Annual Conference of the Association of Diabetes Care and Education Specialists to discuss the latest news from Medtronic and what it means for practitioners as well as patients with diabetes.

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

References:

  1. Medtronic Inc. Medtronic announces FDA approval of SimpleraTM CGM and Global Partnership with Abbott. Medtronic News. August 7, 2024. Accessed August 7, 2024. https://news.medtronic.com/2024-08-07-Medtronic-announces-FDA-approval-of-Simplera-TM-CGM-and-global-partnership-with-Abbott.
Related Videos
Jörn Schattenberg, MD | Credit: Novo Nordisk
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Jörn Schattenberg, MD | Credit: Novo Nordisk
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
© 2024 MJH Life Sciences

All rights reserved.